Jefferies Starts Pardes Biosciences (PRDS) at Buy

January 18, 2022 7:43 AM EST
Get Alerts PRDS Hot Sheet
Price: $2.08 +0.48%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 32 | New: 11
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Jefferies analyst Dennis Ding initiates coverage on Pardes Biosciences (NASDAQ: PRDS) with a Buy rating and a price target of $25.00.

The analyst commented, "Convenient oral pills to broadly treat COVID will drive the world towards an endemic phase and unlock economic recovery since new variants have reduced efficacy from antibodies and vaccines. PRDS has a potent antiviral pill targeting SARS-CoV-2 regardless of variant and has already been partially derisked by competitor PFE with strong efficacy. PRDS is starting pivotal by mid-2022 with many catalysts over next 6-18 months yet only $1B market cap. "

For an analyst ratings summary and ratings history on Pardes Biosciences click here. For more ratings news on Pardes Biosciences click here.

Shares of Pardes Biosciences closed at $13.95 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co